Trials / No Longer Available
No Longer AvailableNCT06028594
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This program is designed to provide access to pozelimab and cemdisiran and document the long-term safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare immune disease that causes red blood cells in your body to break apart.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pozelimab | Subcutaneous (SC) administration |
| DRUG | Cemdisiran | Subcutaneous (SC) administration |
Timeline
- First posted
- 2023-09-08
- Last updated
- 2025-10-20
Source: ClinicalTrials.gov record NCT06028594. Inclusion in this directory is not an endorsement.